Evaluation on Visual Outcome of TMS

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-10-31

Study Completion Date

2027-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to learn if transcranial magnetic stimulation (TMS) can improve the visual outcomes in patients with visual impairment. The main question it aims to answer is:

• Does TMS improve the visual outcome in patients who suffer from visual impairment? Researchers will compare TMS to the control group who will not receive effective TMS treatment) to see if TMS works to improve the visual outcomes of the patients.

Participants will

* Undergo TMS treatment or no effective TMS for consecutive 5 days.
* Visit the clinic once every 2 weeks for checkups and tests.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of TMS Visual Outcome

NCT06600932

Cataract Surgery Experience

NOT_YET_RECRUITING NA

Visual Functional Connectivity and Visual Improvement After TMS/Binocular Treatment

NCT03151200

Amblyopia

WITHDRAWN NA

The Efficacy of Repetitive Transcranial Magnetic Stimulation in Patients With Chronic Subjective Tinnitus

NCT06635967

Tinnitus

RECRUITING NA

Electroencephalography-based Precise Repetitive Transcranial Magnetic Stimulation Treatment

NCT06385405

Major Depressive Disorder (MDD)

RECRUITING NA

Standardization and Optimization of TMS Protocols for the Treatment of PD With Depression or Cognitive Impairment

NCT03552861

TMS Protocols in the Treatment of PD

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Visual Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TMS

Group Type EXPERIMENTAL

TMS

Intervention Type PROCEDURE

TMS treatment in this study indicates a non-invasive procedure called transcranial magnetic simulation (TMS) on visual cortex. The treatment intensity is set as 80% of the threshold of each participant. The treatment will be conducted every day for consecutive 5 days.

Control

Group Type SHAM_COMPARATOR

Control

Intervention Type PROCEDURE

The sham group will be given no real magnetic stimulation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TMS

TMS treatment in this study indicates a non-invasive procedure called transcranial magnetic simulation (TMS) on visual cortex. The treatment intensity is set as 80% of the threshold of each participant. The treatment will be conducted every day for consecutive 5 days.

Intervention Type PROCEDURE

Control

The sham group will be given no real magnetic stimulation.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Post cataract surgery or clear lens
* Best-corrected visual acuity less than 0.1logMAR

Exclusion Criteria

* Diagnosed with cognitive impairment or mental disorders and unable to cooperate with treatment;
* Diagnosed with ocular diseases that affect observation of visual function;
* History of epileptic seizures;
* Long term use of psychotropic drugs；
* Metal implants in the body.

Minimum Eligible Age

6 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

xiangjiazhu

MD, PhD

Responsibility Role PRINCIPAL_INVESTIGATOR